Oral anticoagulation and clinical outcomes in COVID-19: An Italian multicenter experience

[1]  Andrea Gianatti,et al.  Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study , 2020, The Lancet Infectious Diseases.

[2]  G. Boriani,et al.  Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era , 2020, European Journal of Internal Medicine.

[3]  F. Fedele,et al.  Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties , 2020, Journal of clinical medicine.

[4]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[5]  Arthur L. Allen,et al.  Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum , 2020, Journal of Thrombosis and Thrombolysis.

[6]  J. Thachil,et al.  Coagulation abnormalities and thrombosis in patients with COVID-19 , 2020, The Lancet Haematology.

[7]  Yu Hu,et al.  Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome. , 2020, Circulation.

[8]  Q. Nunes,et al.  Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin , 2020, bioRxiv.

[9]  C. Whyte,et al.  Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[10]  Nils Kucher,et al.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.

[11]  Feng Wang,et al.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[12]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[13]  K. Pyrć,et al.  Entry of Human Coronavirus NL63 into the Cell , 2017, Journal of Virology.

[14]  Lisa E. Gralinski,et al.  Molecular pathology of emerging coronavirus infections , 2014, The Journal of pathology.

[15]  Chengyu Jiang,et al.  Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate Proteoglycans , 2011, PloS one.

[16]  E. Young.  The anti-inflammatory effects of heparin and related compounds. , 2008, Thrombosis research.